General Information of the Drug (ID: M6APDG01993)
Name
5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
Synonyms
CHEMBL574666; SCHEMBL5613445; BDBM50300481; 5-(3''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H17NO3
InChI
1S/C18H17NO3/c19-12-14-2-1-3-16(10-14)15-7-4-13(5-8-15)6-9-17(20)11-18(21)22/h1-5,7-8,10,17,20H,6,9,11H2,(H,21,22)
InChIKey
WILNYVYWCSPWAP-UHFFFAOYSA-N
PubChem CID
45483018
TTD Drug ID
D04UBY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-12 (MMP-12)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). [1], [2]
References
Ref 1 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.
Ref 2 Clinical pipeline report, company report or official report of Vernalis.